Search research articles
Contact Us
Filters
Showing results (61-70 of 84) with videos related to
Page
of 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T Powles, I Kayani, K Sharpe, et al.
British Journal of Cancer
|
November 30, 2006
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
J-Y Pierga, J S Reis-Filho, S J Cleator, et al.
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T Powles, J Brown, J Larkin, et al.
ESMO Open
|
June 6, 2025
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
M Sternschuss, N Toumbacaris, J P Das, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
C Suarez, C Rojas, S J Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 84) with videos related to
Sort By:
Page
of 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T Powles, I Kayani, K Sharpe, et al.
British Journal of Cancer
|
November 30, 2006
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy
J-Y Pierga, J S Reis-Filho, S J Cleator, et al.
ESMO Open
|
March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients
S Gupta, M A Climent Duran, S S Sridhar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T Powles, J Brown, J Larkin, et al.
ESMO Open
|
June 6, 2025
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
M Sternschuss, N Toumbacaris, J P Das, et al.
ESMO Open
|
April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial
T Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial
C Suarez, C Rojas, S J Shin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2025
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
T Powles, S A Hussain, M A Climent, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 11, 2025
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
T Powles, S Tagawa, C Vulsteke, et al.
Page
of 9